Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Operating Expenses: 2019-2025

Historic Operating Expenses for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $315.3 million.

  • Revolution Medicines' Operating Expenses rose 79.42% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 58.59%. This contributed to the annual value of $689.5 million for FY2024, which is 38.25% up from last year.
  • Per Revolution Medicines' latest filing, its Operating Expenses stood at $315.3 million for Q3 2025, which was up 19.10% from $264.7 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Operating Expenses peaked at $315.3 million during Q3 2025, and registered a low of $47.5 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $175.7 million (2024), whereas its average is $182.6 million.
  • Data for Revolution Medicines' Operating Expenses shows a peak YoY skyrocketed of 134.60% (in 2023) over the last 5 years.
  • Revolution Medicines' Operating Expenses (Quarterly) stood at $62.4 million in 2021, then grew by 23.51% to $77.0 million in 2022, then skyrocketed by 134.60% to $180.7 million in 2023, then rose by 19.69% to $216.3 million in 2024, then surged by 79.42% to $315.3 million in 2025.
  • Its last three reported values are $315.3 million in Q3 2025, $264.7 million for Q2 2025, and $240.8 million during Q1 2025.